2014; 70(4):437–43.6 6. Gillette C, Prunty L, Wolcott J, Broedel‐Zaugg K. A new lexicon for polypharmacy: Implications for research, practice, and education. Res Social Adm Pharm. 2015; 11(3):468–71.
7 7. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014; 13(1):57–65.
8 8. Tjia J, Velten SJ, Parsons C, Valluri S, Briesacher BA. Studies to reduce unnecessary medication use in frail older adults: a systematic review. Drugs Aging. 2013; 30(5):285–307.
9 9. United States. Congress. Senate. Committee on Finance. Omnibus Budget Reconciliation Act of 1987: explanation of provisions approved by the committee on December 3, 1987 for inclusion in Leadership Deficit Reduction Amendment. Washington: US GPO; 1987:vi.
10 10. Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community‐dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012; 65(9):989–95.
11 11. Steinman MA, Miao Y, Boscardin WJ, Komaiko KD, Schwartz JB. Prescribing quality in older veterans: a multifocal approach. J Gen Intern Med. 2014; 29(10):1379–86.
12 12. Bourgeois FT, Shannon MW, Valim C, Mandl KD. Adverse drug events in the outpatient setting: an 11‐year national analysis. Pharmacoepidemiol Drug Saf. 2010; 19(9):901–10.
13 13. Mannucci PM, Nobili A, Pasina L, Collaborators R. Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register. Intern Emerg Med. 2018; 13(8):1191–200.
14 14. Doan J, Zakrzewski‐Jakubiak H, Roy J, Turgeon J, Tannenbaum C. Prevalence and risk of potential cytochrome P450‐mediated drug‐drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother. 2013; 47(3):324–32.
15 15. Cepeda OA MJ. Polypharmacy, is it another disease? In: Pathy MS SA, Morley JE, eds. Principles and Practice of Geriatric Medicine. 4th ed. John Wiley & Sons, Ltd; 2006:215–21.
16 16. Beyth RJ, Shorr RI. Principles of drug therapy in older patients: rational drug prescribing. Clin Geriatr Med. 2002; 18(3):577–92.
17 17. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: a cross‐sectional and longitudinal study. J Gerontol. 1976; 31(2):155–63.
18 18. David SP. Pharmacogenetics. Prim Care. 2004; 31(3):543–59, ix.
19 19. Brockmoller J, Stingl JC. Multimorbidity, polypharmacy and pharmacogenomics in old age. Pharmacogenomics. 2017; 18(6):515–7.
20 20. American Geriatrics Society. Updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019; 67(4):674–94.
21 21. Curtin D, Gallagher PF, O’Mahony D. Explicit criteria as clinical tools to minimize inappropriate medication use and its consequences. Ther Adv Drug Saf. 2019; 10.
22 22. Jano E, Aparasu RR. Healthcare outcomes associated with Beers’ Criteria: a systematic review. Ann Pharmacother. 2007; 41(3):438–47.
23 23. O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015; 44(2):213–8.
24 24. Anrys P, Boland B, Degryse JM, et al. STOPP/START version 2‐development of software applications: easier said than done? Age Ageing. 2016; 45(5):589–92.
25 25. Gallagher P, O’Mahony D. STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers’ criteria. Age Ageing. 2008; 37(6):673–9.
26 26. Hanlon JT, Schmader KE, Samsa GP, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992; 45(10):1045–51.
27 27. Hanlon JT, Schmader KE. The medication appropriateness index at 20: where it started, where it has been, and where it may be going. Drugs Aging. 2013; 30(11):893–900.
28 28. Whitman AM, DeGregory KA, Morris AL, Ramsdale EE. A comprehensive look at polypharmacy and medication screening tools for the older cancer patient. Oncologist. 2016; 21(6):723–30.
29 29. Steinman MA, Hanlon JT. Managing medications in clinically complex elders: ‘There’s got to be a happy medium’. JAMA. 2010; 304(14):1592–601.
30 30. Chieng JH, Hughes L, Stewart A, Frampton CM, Hanger HC, Jardine DL. Introduction of the Pill Pruner to acute medical care: a simple medication guide to control polypharmacy. Australas J Ageing. 2015; 34(1):58–61.
31 31. Hilmer SN, Mager DE, Simonsick EM, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007; 167(8):781–7.
32 32. Kouladjian L, Gnjidic D, Chen TF, Mangoni AA, Hilmer SN. Drug Burden Index in older adults: theoretical and practical issues. Clin Interv Aging. 2014; 9:1503–15.
33 33. Hilmer SN, Mager DE, Simonsick EM, et al. Drug burden index score and functional decline in older people. Am J Med. 2009; 122(12):1142‐9 e1‐2.
34 34. Salahudeen MS, Hilmer SN, Nishtala PS. Comparison of anticholinergic risk scales and associations with adverse health outcomes in older people. J Am Geriatr Soc. 2015; 63(1):85–90.
35 35. Wilson NM, Hilmer SN, March LM, Cameron ID, Lord SR, Seibel MJ, et al. Associations between drug burden index and falls in older people in residential aged care. J Am Geriatr Soc. 2011; 59(5):875–80.
36 36. Niehoff KM, Rajeevan N, Charpentier PA, Miller PL, Goldstein MK, Fried TR. Development of the Tool to Reduce Inappropriate Medications (TRIM): a clinical decision support system to improve medication prescribing for older adults. Pharmacotherapy. 2016; 36(6):694–701.
37 37. Kuhn‐Thiel AM, Weiss C, Wehling M. Consensus validation of the FORTA (Fit fOR The Aged) List: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging. 2014; 31(2):131–40.
38 38. Pazan F, Weiss C, Wehling M, Forta. The FORTA (Fit fOR The Aged) List 2015: Update of a Validated Clinical Tool for Improved Pharmacotherapy in the Elderly. Drugs Aging. 2016; 33(6):447–9.
39 39. Wehling M, Burkhardt H, Kuhn‐Thiel A, et al. VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification. Age Ageing. 2016; 45(2):262–7.
40 40. Zia A, Kamaruzzaman SB, Tan MP. Polypharmacy and falls in older people: Balancing evidence‐based medicine against falls risk. Postgrad Med. 2015; 127(3):330–7.
41 41. Moulis F, Moulis G, Balardy L, et al. Searching for a polypharmacy threshold associated with frailty. J Am Med Dir Assoc. 2015; 16(3):259–61.
42 42. Chiu MH, Lee HD, Hwang HF, Wang SC, Lin MR. Medication use and fall‐risk assessment for falls in an acute care hospital. Geriatr Gerontol Int. 2015; 15(7):856–63.
43 43. Jyrkka J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging. 2009; 26(12):1039–48.
44 44. Gomez C, Vega‐Quiroga S, Bermejo‐Pareja F, Medrano MJ, Louis ED, Benito‐Leon J. Polypharmacy in the elderly: a marker of increased risk of mortality in a population‐based prospective study (NEDICES). Gerontology. 2015; 61(4):301–9.
45 45.
